On January 24, 2020, OncoSec Medical Incorporated announced that it is texting to ask shareholders to vote yes on the Company’s proxy card for the strategic transaction with China Grand Pharma and Sirtex, which provides an immediate and crucial $30 million cash infusion at a premium and eliminates the need to raise capital for the foreseeable future. The Company added that, this deal has support from both Institutional Shareholder Services and Glass Lewis, independent proxy advisory firms.